In individuals who are deficient in CYP2D6, coadministration of modafinil with substrates of CYP2D6 that have ancillary routes of elimination through CYP2C19 (eg, tricyclic antidepressants and selective serotonin reuptake inhibitors) may perhaps lead to elevated circulating levels of these medications and need dose adjustment (Robertson et al 2000;